Graft versus Host Disease (GvHD) Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

By Company 1.2.2. Analysis by Phase 1.2.3. By Molecule Type 1.2.4. By region 2. Disease Overview 2.1.1. Introduction 2.1.2. Classification 2.1.3. Symptoms 2.1.4. Causes 2.1.5. Diagnoses 2.1.6. Treatment 2.1.7. Epidemiology 3. Executive Summary 4. Market Dynamics 4.1. Drivers 4.2. Restraints 4.3. Opportunities 5. Pipeline Analysis/Outlook 5.1. Analysis by Company 5.2. Analysis by Phase 5.2.1. Phase of Development 5.2.1.1. Introduction 5.2.1.1.1. Drug Profiling • Drug Name • Generic Name • Synonyms • Company • Collaborator • Route of administration • Target • Mechanism of Action • Technology • Molecule type • CAS Number • Weight • Chemical Formula • IUPAC name • ATC code 5.2.1.1.2. Strategic Developments 5.2.1.1.3. Clinical trials 5.2.1.1.4. Clinical trial results 5.2.1.1.5. Patents 5.2.1.1.6. Technology 5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph) 5.3. By Molecule type 5.4. Analysis by Region 6. Company profiling 6.1. AbGenomics International, Inc. 6.1.1. Introduction 6.1.2. Financials 6.1.3. Products and Services 6.1.4. SWOT 6.2. Adienne Pharma & Biotech 6.2.1. Introduction 6.2.2. Financials 6.2.3. Products and Services 6.2.4. SWOT 6.3. Alexion Pharmaeuticals 6.3.1. Introduction 6.3.2. Financials 6.3.3. Products and Services 6.3.4. SWOT 6.4. Alpine immune Sciences 6.4.1. Introduction 6.4.2. Financials 6.4.3. Products and Services 6.4.4. SWOT 6.5. Amgen 6.5.1. Introduction 6.5.2. Financials 6.5.3. Products and Services 6.5.4. SWOT 6.6. Anaptysbio, Inc. 6.6.1. Introduction 6.6.2. Financials 6.6.3. Products and Services 6.6.4. SWOT 6.7. Apceth Biopharma 6.7.1. Introduction 6.7.2. Financials 6.7.3. Products and Services 6.7.4. SWOT 6.8. Aptevo Therapeutics 6.8.1. Introduction 6.8.2. Financials 6.8.3. Products and Services 6.8.4. SWOT 6.9. Argenx 6.9.1. Introduction 6.9.2. Financials 6.9.3. Products and Services 6.9.4. SWOT 6.10. Athersys, Inc. 6.10.1. Introduction 6.10.2. Financials 6.10.3. Products and Services 6.10.4. SWOT 6.11. Bellicum Pharmaceuticals, Inc. 6.11.1. Introduction 6.11.2. Financials 6.11.3. Products and Services 6.11.4. SWOT 6.12. Cell2B 6.12.1. Introduction 6.12.2. Financials 6.12.3. Products and Services 6.12.4. SWOT 6.13. Cellect Biotherapeutics Ltd. 6.13.1. Introduction 6.13.2. Financials 6.13.3. Products and Services 6.13.4. SWOT 6.14. CSL Behring 6.14.1. Introduction 6.14.2. Financials 6.14.3. Products and Services 6.14.4. SWOT 6.15. Cynata Therapeutics 6.15.1. Introduction 6.15.2. Financials 6.15.3. Products and Services 6.15.4. SWOT 6.16. CytoDyn, Inc. 6.16.1. Introduction 6.16.2. Financials 6.16.3. Products and Services 6.16.4. SWOT 6.17. Dr. Falk Pharma GmbH 6.17.1. Introduction 6.17.2. Financials 6.17.3. Products and Services 6.17.4. SWOT 6.18. ElsaLys Biotech SA 6.18.1. Introduction 6.18.2. Financials 6.18.3. Products and Services 6.18.4. SWOT 6.19. Engene Inc 6.19.1. Introduction 6.19.2. Financials 6.19.3. Products and Services 6.19.4. SWOT 6.20. Enlivex Therapeutics ltd 6.20.1. Introduction 6.20.2. Financials 6.20.3. Products and Services 6.20.4. SWOT 6.21. Escape Therapeutics, Inc. 6.21.1. Introduction 6.21.2. Financials 6.21.3. Products and Services 6.21.4. SWOT 6.22. Fate Therapeutics 6.22.1. Introduction 6.22.2. Financials 6.22.3. Products and Services 6.22.4. SWOT 6.23. Genentech, Inc. 6.23.1. Introduction 6.23.2. Financials 6.23.3. Products and Services 6.23.4. SWOT 6.24. Generon Pharmaceutical Technology 6.24.1. Introduction 6.24.2. Financials 6.24.3. Products and Services 6.24.4. SWOT 6.25. Gilead 6.25.1. Introduction 6.25.2. Financials 6.25.3. Products and Services 6.25.4. SWOT 6.26. GlaxoSmithKline 6.26.1. Introduction 6.26.2. Financials 6.26.3. Products and Services 6.26.4. SWOT 6.27. Immplacate Health 6.27.1. Introduction 6.27.2. Financials 6.27.3. Products and Services 6.27.4. SWOT 6.28. Inspyr Therapeutics 6.28.1. Introduction 6.28.2. Financials 6.28.3. Products and Services 6.28.4. SWOT 6.29. Janssen Pharmaceuticals 6.29.1. Introduction 6.29.2. Financials 6.29.3. Products and Services 6.29.4. SWOT 6.30. Jazz Pharmaceuticals Inc. 6.30.1. Introduction 6.30.2. Financials 6.30.3. Products and Services 6.30.4. SWOT 6.31. Kadmon Holdings, Inc. 6.31.1. Introduction 6.31.2. Financials 6.31.3. Products and Services 6.31.4. SWOT 6.32. Kalytera Therapeutics, Inc. 6.32.1. Introduction 6.32.2. Financials 6.32.3. Products and Services 6.32.4. SWOT 6.33. Kamada, Ltd. 6.33.1. Introduction 6.33.2. Financials 6.33.3. Products and Services 6.33.4. SWOT 6.34. Kiadis Pharma 6.34.1. Introduction 6.34.2. Financials 6.34.3. Products and Services 6.34.4. SWOT 6.35. Kymab 6.35.1. Introduction 6.35.2. Financials 6.35.3. Products and Services 6.35.4. SWOT 6.36. MaaT Pharma 6.36.1. Introduction 6.36.2. Financials 6.36.3. Products and Services 6.36.4. SWOT 6.37. Mallinckrodt Pharmaceuticals 6.37.1. Introduction 6.37.2. Financials 6.37.3. Products and Services 6.37.4. SWOT 6.38. Mesoblast Ltd 6.38.1. Introduction 6.38.2. Financials 6.38.3. Products and Services 6.38.4. SWOT 6.39. MolMed S.p.A. 6.39.1. Introduction 6.39.2. Financials 6.39.3. Products and Services 6.39.4. SWOT 6.40. NapaJen Pharma, Inc. 6.40.1. Introduction 6.40.2. Financials 6.40.3. Products and Services 6.40.4. SWOT 6.41. Neovii Biotech 6.41.1. Introduction 6.41.2. Financials 6.41.3. Products and Services 6.41.4. SWOT 6.42. Novartis 6.42.1. Introduction 6.42.2. Financials 6.42.3. Products and Services 6.42.4. SWOT 6.43. Ocugen, Inc. 6.43.1. Introduction 6.43.2. Financials 6.43.3. Products and Services 6.43.4. SWOT 6.44. OncoImmune 6.44.1. Introduction 6.44.2. Financials 6.44.3. Products and Services 6.44.4. SWOT 6.45. Osiris 6.45.1. Introduction 6.45.2. Financials 6.45.3. Products and Services 6.45.4. SWOT 6.46. Regimmune Co., Ltd. 6.46.1. Introduction 6.46.2. Financials 6.46.3. Products and Services 6.46.4. SWOT 6.47. Seattle Genetics, Inc. 6.47.1. Introduction 6.47.2. Financials 6.47.3. Products and Services 6.47.4. SWOT 6.48. Seres Therapeutics 6.48.1. Introduction 6.48.2. Financials 6.48.3. Products and Services 6.48.4. SWOT 6.49. Takeda Oncology 6.49.1. Introduction 6.49.2. Financials 6.49.3. Products and Services 6.49.4. SWOT 6.50. Targazyme, Inc. 6.50.1. Introduction 6.50.2. Financials 6.50.3. Products and Services 6.50.4. SWOT 6.51. TxCell 6.51.1. Introduction 6.51.2. Financials 6.51.3. Products and Services 6.51.4. SWOT 6.52. Vault Pharma 6.52.1. Introduction 6.52.2. Financials 6.52.3. Products and Services 6.52.4. SWOT 6.53. Xenikos B.V. 6.53.1. Introduction 6.53.2. Financials 6.53.3. Products and Services 6.53.4. SWOT 6.54. XL-protein GmbH 6.54.1. Introduction 6.54.2. Financials 6.54.3. Products and Services 6.54.4. SWOT 6.55. Zai Lab 6.55.1. Introduction 6.55.2. Financials 6.55.3. Products and Services 6.55.4. SWOT List of Tables List of Figures